lack
anim
model
human
noroviru
hunov
hinder
develop
therapeut
strategi
studi
demonstr
commonli
use
cholesterollow
statin
medic
simvastatin
increas
hunov
replic
vitro
replicon
system
also
enhanc
hunov
infect
gnotobiot
gn
pig
model
contrast
oral
treatment
interferon
ifn
reduc
hunov
infect
young
piglet
histoblood
group
antigen
enterocyt
treat
oral
mgkgday
simvastatin
day
later
pig
inocul
oral
hunov
strain
treat
simvastatin
day
simvastatin
induc
significantli
earlier
onset
longer
durat
hunov
fecal
shed
treat
pig
frequent
higher
fecal
viral
titer
simvastatin
impair
poli
c
induc
ifna
express
macrophag
dendrit
cell
possibl
due
lower
tolllik
receptor
tlr
express
howev
mechan
relat
interferon
regulatori
factor
nuclear
factor
kappa
b
signal
pathway
thu
enhanc
earlier
infect
hunov
simvastatintr
pig
coincid
inhibitori
effect
simvastatin
innat
immun
contrast
increas
hunov
shed
simvastatin
induc
viral
shed
treatment
period
reduc
curtail
hunovinocul
pig
pretreatedtr
human
ifna
find
first
indic
ifna
potenti
antivir
therapi
hunov
base
intrigu
novel
find
use
gn
pig
model
confirm
hunov
infect
alter
treatment
simvastatin
ifna
collect
find
indic
gn
pig
use
model
test
immunomodul
efficaci
antivir
hunov
human
noroviru
hunov
singlestrand
posit
sens
rna
viru
member
calicivirida
famili
viru
lead
pathogen
caus
foodor
waterborn
gastroenter
hunov
estim
caus
million
case
ill
annual
us
account
approxim
foodborn
ill
caus
differ
bacteria
parasit
virus
clinic
patholog
featur
hunov
infect
includ
short
incub
period
hr
prior
onset
clinic
sign
vomit
diarrhea
although
asymptomat
infect
occur
frequent
ii
acut
selflimit
infect
often
prolong
fecal
viru
shed
iii
lymphocyt
atroph
enter
hunov
classifi
distinct
genogroup
gi
gii
giv
subdivid
differ
hunov
genotyp
last
year
gii
hunov
respons
major
hunov
outbreak
possibl
due
sever
viral
host
factor
review
recent
broader
bind
host
receptor
hunov
ii
incomplet
herd
immun
variant
iii
higher
mutat
rate
polymeras
viral
capsid
protein
domain
protrud
variabl
region
believ
recogn
host
cellular
receptor
contribut
establish
viral
infect
histoblood
group
antigen
hbga
consid
cellular
receptor
coreceptor
determin
host
suscept
certain
hunov
individu
blood
type
h
secretor
suscept
viru
infect
individu
nonsecretor
secretor
blood
type
b
howev
emerg
hunov
strain
bind
hbga
test
vitro
observ
impli
host
factor
affect
infect
certain
genogroup
genotyp
hunov
hunov
infect
gener
selflimit
induc
sever
ill
fatal
diseas
immunocompromis
patient
specif
organ
recipi
receiv
longterm
chemotherapi
hematopoiet
stem
cell
transplant
young
elderli
also
risk
due
high
exposur
rate
hunov
infect
commun
set
child
care
center
nurs
home
hospit
etc
notabl
common
use
statin
medic
lower
serum
cholesterol
level
prevent
cardiovascular
diseas
signific
risk
factor
exacerb
hunov
diseas
sever
increas
relat
fatal
rate
condit
requir
effect
therapeut
strategi
hunov
infect
howev
lack
small
anim
model
hunov
hinder
develop
test
hunov
antivir
vaccin
gnotobiot
gn
pig
suscept
oral
infect
hunov
strain
emerg
gii
hunov
strain
hunovinfect
gn
pig
shed
viru
fece
incub
period
hr
hunov
gn
pig
similar
hr
observ
human
experiment
infect
snow
mountain
viru
longer
fecal
hunov
shed
gn
pig
infect
strain
similar
observ
human
case
also
like
human
possess
secretor
phenotyp
gn
pig
express
hbga
enterocyt
differ
hbga
phenotyp
h
shown
influenc
suscept
gn
pig
hunov
infect
norwalk
viru
repliconharbor
cell
system
viral
rna
protein
level
increas
treatment
cholesterol
lower
drug
simvastatin
act
hmgcoa
reductas
inhibitor
statin
treatment
reduc
cellular
cholesterol
level
follow
high
express
lowdens
lipoprotein
receptor
ldlr
gene
compens
lower
cellular
cholesterol
level
result
indic
cholesterol
pathway
may
associ
enhanc
replic
hunov
vitro
although
relat
mechan
unclear
statin
also
involv
varieti
immun
respons
immunosuppress
inhibit
major
histocompat
complex
mhc
class
ii
express
antigen
present
cell
mice
promot
gener
regulatori
cell
mice
impair
lipopolysaccharideinduc
tolllik
receptor
tlr
inflammatori
respons
human
embryon
cell
aim
studi
determin
statin
also
enhanc
hunov
infect
vivo
gn
pig
model
hunov
infect
gn
pig
treat
highdos
simvastatin
inocul
hunov
strain
investig
enhanc
earlier
infect
hunov
seen
simvastatintr
pig
correl
inhibitori
effect
simvastatin
innat
immun
final
investig
effect
innat
immun
mediat
ifna
hunov
infect
gn
pig
model
simvastatin
treatment
lower
serum
cholesterol
level
gn
pig
result
increas
earli
ldlr
gene
express
porcin
enterocyt
cell
line
serum
cholesterol
level
monitor
measur
pharmacolog
activ
simvastatin
gn
pig
simvastatintr
pig
significantli
decreas
serum
cholesterol
level
mgdl
day
treatment
began
time
lower
level
untreat
pig
mgdl
period
fig
investig
revers
relationship
exist
cholesterol
level
ldlr
gene
express
porcin
jejun
epitheli
cell
line
intestin
epitheli
cell
cell
type
critic
initi
hunov
infect
cell
treat
multipl
concentr
mm
mm
mm
mm
simvastatin
ldlr
gene
express
analyz
quantit
realtim
rtpcr
qrtpcr
hour
treatment
mm
simvastatin
ldlr
gene
express
level
cell
significantli
increas
compar
mm
treat
group
fig
hour
treatment
mm
simvastatin
ldlr
gene
express
level
significantli
increas
time
compar
untreat
group
fig
significantli
earlier
onset
hunov
shed
observ
simvastatintr
pig
began
shed
mean
postinocul
day
pid
compar
mean
pid
untreat
pig
fig
significantli
longer
durat
hunov
shed
also
observ
simvastatintr
pig
shed
mean
day
compar
mean
day
untreat
pig
fig
mean
daili
fecal
hunov
titer
compar
statist
simvastatintr
untreat
pig
trial
due
high
variabl
mean
viral
titer
among
independ
trial
significantli
higher
viral
rna
titer
detect
simvastatintr
pig
untreat
pig
trial
log
genom
equival
ge
ml
vs
log
geml
trial
log
geml
vs
log
geml
fig
howev
signific
differ
observ
trial
immunohistochemistri
ihc
result
show
hunov
antigen
cytoplasm
surfac
enterocyt
lamina
propria
cell
fig
support
fecal
viru
shed
result
hunov
replic
infect
intestin
ihcposit
cell
small
intestin
larg
intestin
epitheli
cell
also
express
similar
level
hbga
small
intestin
fig
howev
hunov
inocul
simvastatintr
untreat
gn
pig
pronounc
histolog
chang
evid
small
larg
intestin
gn
pig
sideeffect
oral
treatment
highdos
simvastatin
control
experiment
condit
hunovinfect
pig
show
diarrhea
wherea
mild
diarrhea
notic
observ
statintr
pig
day
statin
treatment
hbga
h
type
pig
equal
suscept
hunov
infect
gn
pig
use
studi
posit
either
hbga
fig
hbga
antigen
distribut
surfac
cytoplasm
epitheli
cell
line
intestin
salivari
gland
pulmonari
bronchial
renal
tubular
epitheli
cell
fig
similar
ihc
condit
amount
antigen
pig
greater
intestin
posit
tissu
compar
antigen
h
pig
fig
howev
signific
differ
onset
durat
fecal
viru
shed
found
h
pig
fig
b
despit
higher
express
level
antigen
significantli
lower
viral
rna
titer
log
geml
detect
fece
pig
log
geml
h
pig
differ
observ
simvastatintr
h
pig
fig
simvastatin
impair
induct
ifna
macrophag
dendrit
cell
possibl
due
lower
express
treatment
vivo
data
show
enhanc
earli
infect
hunov
suggest
potenti
subvers
innat
immun
relat
simvasatin
treatment
thu
investig
simvastatin
inhibit
capac
macrophag
dendrit
cell
dc
produc
ifna
stimul
poli
c
trigger
induct
ifna
gener
ifna
detect
cultur
supernat
macrophag
dc
treat
either
simvastatin
mock
porcin
pulmonari
alveolar
macrophag
pam
ifna
level
uml
releas
simvastatin
poli
c
treat
pam
significantli
lower
uml
poli
c
onlytr
pam
hour
poli
c
treatment
fig
peripher
blood
mononuclear
cell
pbmc
deriv
macrophag
respond
less
treatment
mgml
poli
c
compar
pam
treat
mgml
poli
c
tabl
possibl
due
lower
ratio
harvest
adher
macrophag
pbmc
similar
observ
pam
significantli
lower
ifna
level
uml
observ
simvastatintr
enrich
intestin
dc
hour
poli
c
treatment
compar
uml
poli
c
treatment
alon
tabl
mean
percentag
sem
cell
n
simvastatin
poli
c
treat
intestin
macrophag
hour
poli
c
treatment
significantli
lower
compar
n
poli
c
alon
repres
flow
cytometr
profil
illustr
fig
c
gene
express
level
nfkb
mainli
involv
poli
c
induc
ifn
product
analyz
investig
possibl
mechan
underli
subvers
innat
immun
induc
simvastatin
pam
intestin
dc
although
simvastatin
alon
induc
ifna
product
pam
fig
increas
express
nfkb
gene
found
simvastatintr
pam
fig
b
cotreat
simvastatin
poli
c
synergist
result
increas
gene
express
nfkb
hour
poli
c
treatment
howev
gene
express
level
nfkb
reduc
poli
c
onlytr
pam
simvastatin
poli
c
treat
pam
compar
treatment
swine
ifna
level
decreas
poli
c
simvastatintr
pam
dc
hunov
infect
enhanc
vivo
therefor
investig
whether
fecal
hunov
shed
ie
hunov
replic
gut
infect
gn
pig
alter
treatment
ifna
oral
treatment
gn
pig
natur
human
ifna
nhifna
intern
unit
iu
kgday
reduc
curtail
viru
shed
treat
anim
treatment
period
pid
compar
untreat
anim
fig
treatment
significantli
delay
onset
viru
shed
day
treat
pig
began
shed
mean
pid
compar
mean
pid
untreat
pig
fig
nhifna
treatment
period
pid
significantli
shorter
durat
hunov
shed
observ
nhifnatr
pig
shed
mean
day
compar
mean
day
untreat
pig
fig
treatment
period
significantli
lower
qrtpcrposit
rate
fecal
sampl
test
also
observ
nhifnatr
pig
untreat
pig
significantli
lower
viral
rna
titer
fece
log
geml
treat
pig
vs
log
geml
untreat
pig
fig
howev
pid
nhifnatreat
discontinu
significantli
increas
viral
shed
titer
note
nhifnatr
pig
log
geml
compar
untreat
pig
log
geml
fig
pid
signific
differ
durat
fecal
viru
shed
qrtpcrposit
rate
fecal
sampl
test
nhifnatr
pig
untreat
pig
fig
repeat
studi
addit
pig
need
investig
termin
nhifn
treatment
result
higher
viral
shed
titer
post
ifna
treatment
neg
control
pig
shed
detect
viral
rna
fece
throughout
experi
demonstr
use
simvastatin
enhanc
hunov
infect
gn
pig
model
thu
use
may
also
support
growth
hunov
cell
cultur
also
verifi
increas
infect
hunov
may
associ
inhibitori
effect
statin
innat
immun
ifna
observ
might
explain
exacerb
hunov
diseas
relat
higher
mortal
describ
statintr
human
immunosuppress
effect
use
statin
propos
immunomodulatori
therapi
sever
influenza
viru
infect
larg
amount
innat
ifna
cytokin
involv
addit
show
oral
treatment
nhifna
curtail
earli
hunov
fecal
shed
gn
pig
model
hunov
vaccin
avail
use
effect
antivir
ifna
test
control
multipl
genogroup
genotyp
hunov
includ
variant
emerg
year
find
hunov
infect
gn
pig
enhanc
simvastatin
treatment
reduc
oral
treatment
nhifna
suggest
gn
pig
use
model
test
efficaci
antivir
hunov
surrog
model
hunov
murin
nov
mnv
infect
mice
use
investig
role
specif
immunolog
factor
type
ii
ifn
host
defens
howev
differ
pathogenesi
mnv
infect
system
spread
rais
concern
extrapol
find
hunov
restrict
gastrointestin
infect
chimpanze
model
recent
establish
evalu
efficaci
daili
viral
titer
mean
monitor
qrtpcr
shown
c
monitor
continu
week
infect
termin
pcr
result
neg
log
geml
consecut
day
data
independ
anim
trial
combin
pcr
test
perform
duplic
triplic
addit
analysi
also
conduct
accord
hbga
phenotyp
anim
bar
repres
mean
sem
simvastatin
hunov
vs
hunov
alon
pig
vs
h
pig
unpair
twotail
mannwhitney
test
anim
number
n
indic
bottom
graph
dot
line
indic
detect
limit
log
geml
qrtpcr
vlpderiv
vaccin
infect
gi
gii
hunov
chimpanze
develop
serum
antibodi
respons
intraven
inject
viru
intramuscular
inject
norwalk
vlp
protect
norwalk
viru
challeng
gii
hunov
infect
chimpanze
model
howev
compromis
lack
avail
chimpanze
find
oral
infect
chimpanze
hunov
fail
induc
gastroenter
diseas
compar
human
case
well
intraven
rout
requir
viral
challeng
studi
although
hunov
infect
gn
pig
induc
mild
enter
diseas
gn
pig
suscept
oral
infect
strain
reaffirm
result
previou
studi
use
close
relat
hunov
strain
emerg
hunov
strain
fecal
hunov
shed
pattern
gn
pig
peak
viral
titer
earli
stage
infect
also
typic
acut
enter
viral
infect
pig
rotaviru
porcin
epidem
diarrhea
viru
howev
hunov
shed
infect
gn
pig
maintain
week
viral
inocul
unclear
requir
investig
cholesterol
biosynthesi
metabol
mainli
mediat
hepat
enzym
hmgcoa
reductas
statin
act
competit
inhibitor
hmgcoa
reductas
reduc
product
cholesterol
liver
human
studi
show
statin
lower
serum
cholesterol
level
gn
pig
possibl
due
similar
cholesterol
pathway
swine
human
report
previous
hepat
cholesterol
store
deplet
liver
increas
express
ldlr
lead
uptak
ldl
plasma
compens
lower
cellular
cholesterol
level
sever
rna
virus
manipul
cholesterol
pathway
divers
way
effici
viral
infect
replic
exemplifi
nov
comparion
hepat
c
viru
hcv
coronaviru
exampl
low
cellular
cholesterol
level
high
cellular
ldlr
express
follow
statin
treatment
contribut
increas
viru
replic
verifi
vitro
replicon
system
studi
also
show
increas
ldlr
express
level
cell
porcin
jejun
cell
line
treat
simvastatin
might
similarli
contribut
enhanc
hunov
replic
gastrointestin
tract
ongo
vitro
studi
also
found
hunov
rna
titer
supernat
lysat
sampl
cell
treat
simvastatin
slightli
increas
trial
use
strain
compar
control
without
simvastatin
differ
significantli
cell
cultur
use
strain
latter
previous
report
data
indic
posit
inconsist
effect
simvastatin
hunov
replic
vitro
possibl
depend
hunov
strain
differ
environment
condit
hunov
replic
vitro
versu
vivo
paper
describ
detail
comprehens
vitro
cell
cultur
find
prepar
takanashi
et
al
unpublish
data
addit
cholesterol
lower
effect
inhibitori
effect
statin
innat
immun
also
might
influenc
immunolog
cellular
microenviron
effici
hunov
replic
studi
simvastatin
impair
innat
immun
inhibit
product
ifna
induc
poli
c
pam
intestin
dc
observ
similar
result
vitro
studi
use
cell
show
inhibitori
effect
simvastatin
immun
respons
tumor
necrosi
factor
tnf
nevertheless
notabl
observ
gn
pig
human
infect
hunov
contrari
effect
statin
reduc
replic
hcv
repliconharbor
cell
posit
correl
cellular
cholesterol
level
entri
coronavirus
gvmnv
host
cell
confirmatori
data
need
defin
role
cholesterol
pathway
pathogenesi
hunov
although
simvastatin
treatment
inhibit
ifna
product
found
gene
express
nfkb
simvastatintr
pam
increas
rather
decreas
activ
nfkb
kinas
share
properti
among
tlr
includ
simvastatin
cellular
byproduct
could
trigger
tlr
stimul
nfkb
gene
express
notabl
hour
poli
c
treatment
gene
express
level
nfkb
poli
c
onlytr
cell
reduc
remark
compar
treatment
earlier
timepoint
observ
could
explain
cellular
neg
feedback
effect
mediat
product
ifna
also
notabl
similar
result
occur
simvastatin
poli
c
treat
cell
possibl
due
reduc
ifna
level
simvastatin
treatment
least
four
famili
transcript
factor
activ
dsrna
relat
nfkb
cjun
activ
transcript
factor
besid
lower
express
macrophag
simvastatin
treatment
thought
mainli
respons
reduct
ifna
product
statin
poli
c
treat
cell
ifnmedi
signal
pathway
might
involv
impair
innat
immun
simvastatin
type
ifn
essenti
earli
viral
clearanc
develop
adapt
immun
respons
crucial
mediat
innat
antivir
immun
respons
ifna
effect
antivir
treatment
viral
infect
hcv
influenza
signal
transduc
activ
depend
ifn
stimul
essenti
control
murin
nov
mnv
infect
although
mnv
caus
diseas
immunocompet
mice
oral
mnv
infect
caus
fatal
system
diseas
mice
lack
either
type
type
ii
interferon
receptor
critic
ifn
signal
sever
studi
suggest
repeat
oral
treatment
nhifna
may
effect
treat
acut
viral
gastroenter
relat
coronaviru
rotaviru
domest
pig
similarli
studi
show
oral
administr
nhifna
inhibit
infect
replic
hunov
fecal
hunov
shed
curtail
gn
pig
model
nhifna
formul
stabl
low
ph
stomach
degrad
nhifna
varieti
intestin
enzym
appear
slow
enough
allow
nhifna
reach
ifna
receptor
cell
mucos
lymphoid
tissu
oral
caviti
intestin
tabl
therapeut
effect
nhifna
might
relat
immunostimulatori
effect
oral
deliv
nhifna
promot
system
innat
immun
increas
express
level
innat
immunityrel
gene
ifnstimul
gene
isg
tnfa
phagocyt
capac
phagocyt
studi
larger
number
anim
need
determin
effect
dose
regimen
nhifna
prevent
treat
hunov
infect
elucid
immunolog
molecular
mechan
relat
antivir
effect
ifna
base
effect
combin
nhifna
preand
posttreat
nhifna
treatment
need
test
therapeut
futur
studi
use
gn
pig
model
five
six
dayold
piglet
treat
oral
iu
nhifna
day
pid
pid
day
nhifna
treatment
inocul
oral
hunov
subsequ
treat
nhifna
iu
day
nhifna
treatment
hunov
inocul
clinic
sign
fecal
viru
shed
monitor
daili
shed
termin
data
independ
anim
trial
combin
pcr
test
perform
duplic
triplic
durat
viru
shed
nhifnatr
untreat
pig
analyz
base
nhifna
treatment
period
ie
treatment
pid
posttreat
pid
overal
pid
bar
repres
mean
sem
nhifna
hunov
vs
hunov
alon
unpair
twotail
mannwhitney
test
anim
number
n
indic
bottom
graph
dot
line
indic
detect
limit
log
geml
qrtpcr
clinic
trial
mechan
fecal
viru
shed
recur
increas
viral
rna
titer
nhifntreat
gn
pig
compar
untreat
pig
nhifn
treatment
discontinu
need
investig
howev
hypothes
period
nhifn
treatment
ifn
signal
pathway
might
regul
neg
feedback
ifn
produc
cell
intestin
thu
termin
treatment
distinct
condit
ifn
system
might
hinder
induct
product
ifna
ifn
contain
cell
antivir
activ
hunov
conclus
simvastatin
treatment
increas
hunov
infect
gn
pig
model
possibl
due
inhibitori
effect
innat
immun
well
cholesterol
lower
effect
report
previous
find
could
partial
explain
exacerb
hunov
diseas
statintr
human
test
nhifna
antivir
hunov
use
gn
pig
model
also
reveal
ifna
potenti
hunov
antivir
therapi
develop
hunov
antivir
import
hunov
caus
largescal
epidem
signific
mortal
immunocompromis
elderli
young
patient
thu
gn
pig
model
hunov
allow
test
new
treatment
modal
hunov
infect
new
knowledg
antivir
mechan
innat
adapt
immun
cell
kindli
provid
dr
bruce
schultz
kansa
state
univers
cell
maintain
dulbecco
modifi
eagl
mediumnutri
ham
mixtur
invitrogen
carlsbad
ca
fetal
bovin
serum
fb
hyclon
laboratori
inc
logan
ut
insulintransferrinsodium
selenit
roch
mannheim
germani
epiderm
growth
factor
ngml
invitrogen
us
strain
genbank
access
number
use
viral
inoculum
studi
isol
stool
sampl
young
child
wateri
diarrhea
stool
sampl
screen
enter
virus
includ
gi
hunov
rotaviru
group
b
c
sapoviru
astroviru
adenoviru
revers
transcript
rt
pcr
pcr
respect
describ
previous
nearterm
pig
deriv
hysterectomi
maintain
steril
isol
unit
ihc
use
monoclon
antibodi
human
immucor
norcross
ca
covanc
research
product
inc
dedham
determin
ah
phenotyp
fresh
bucal
cell
formalinfix
paraffinembed
intestin
salivari
glandular
tissu
gn
pig
institut
anim
care
use
committe
iacuc
ohio
state
univers
approv
protocol
relat
anim
experi
studi
anim
use
studi
also
handl
accord
guidelin
iacuc
ohio
state
univers
piglet
randomli
assign
one
four
group
simvastatin
hunov
n
hunov
alon
n
mock
n
simvastatin
alon
n
lower
serum
cholesterol
level
prior
viru
infect
five
seven
dayold
piglet
first
treat
oral
mgdaypig
approxim
kg
bodi
weight
simvastatin
zocor
merck
co
inc
whitehous
station
nj
day
treatment
infect
oral
ge
hunov
subsequ
treat
half
dose
pretreat
day
simvastatin
treatment
hunov
inocul
monitor
clinic
sign
daili
acut
pid
stage
hunov
infect
pig
per
group
euthan
histopaholog
examin
viru
fecal
shed
termin
determin
qrtpcr
ie
later
pid
stage
infect
pig
per
group
euthan
nhifna
kindli
provid
dr
joseph
cummin
amarillo
bioscienc
inc
amarillo
tx
piglet
randomli
assign
one
three
group
constitut
independ
trial
nhifnatr
hunovinfect
n
nhifnauntr
hunovinfect
n
neg
control
n
five
six
dayold
piglet
approxim
kg
bodi
weight
treat
oral
iu
nhifna
day
pid
pid
day
nhifna
treatment
infect
oral
ge
hunov
subsequ
treat
nhifna
iu
day
nhifna
treatment
hunov
inocul
clinic
sign
fecal
viru
shed
monitor
daili
shed
termin
total
serum
cholesterol
level
assess
simvastatin
treatment
trial
use
amplex
red
cholesterol
assay
kit
invitrogen
describ
previous
total
cholesterol
extract
chloroformmethanoldoubledistil
water
volvolvol
chloroform
phase
separ
mix
volum
polyoxyethylen
ether
sigmaaldrich
st
loui
mo
dri
resuspend
assay
reaction
buffer
kit
treatment
duplic
addit
sixwel
plate
cell
lysat
prepar
measur
protein
content
use
bca
protein
assay
kit
biorad
hercul
ca
concentr
total
cholesterol
normal
protein
content
rectal
swab
collect
daili
anim
throughout
experi
gii
hunov
fecal
shed
titer
determin
taqman
realtim
rtpcr
primer
set
probe
describ
previous
detect
limit
pcr
assay
ge
per
reaction
determin
base
standard
curv
gener
use
serial
dilut
plasmid
dna
carri
amplicon
limit
viral
rna
detect
qrtpcr
assay
log
geml
recombin
baculoviru
carri
capsid
protein
gene
strain
genbank
access
number
gener
use
baculodirect
tm
baculoviru
express
system
invitrogen
accord
manufactur
instruct
briefli
gateway
entri
clone
contain
pentr
tm
gener
use
baculodirect
tm
linear
dna
perform
lr
recombin
reaction
gener
recombin
baculoviru
dna
carri
insect
cell
transfect
recombin
reaction
product
cell
contain
recombin
baculoviru
dna
posit
select
ganciclovir
express
capsid
protein
cell
cultur
supernat
examin
immunoblot
use
guinea
pig
antiserum
hunov
strain
recombin
baculovirus
propag
prepar
viru
stock
high
titer
routin
vlp
express
product
purif
vlp
perform
describ
previous
protein
concentr
quantifi
use
bradford
method
vlp
neg
stain
phosphotungst
acid
ph
examin
transmiss
electron
microscopi
describ
previous
hyperimmun
serum
hunov
vlp
gener
use
guinea
pig
accord
approv
iacuc
protocol
previous
describ
small
duodenum
proxim
middl
distal
jejunum
ileum
larg
cecum
colon
intestin
tissu
major
organ
lung
liver
heart
kidney
spleen
lymph
node
examin
grossli
histolog
test
ihc
nov
antigen
detect
tissu
agematch
mock
control
test
histolog
comparison
neg
control
ihc
ihc
perform
formalinfix
paraffinembed
tissu
fresh
frozen
tissu
use
guinea
pig
hyperimmun
antisera
vlp
hunov
describ
previous
pam
cellsml
collect
lung
tendayold
uninfect
gn
pig
use
asept
techniqu
previous
describ
cell
cellswel
seed
onto
cell
plate
well
randomli
assign
treatment
group
treatment
simvastatin
alon
simvastatin
poli
c
poli
c
alon
pam
first
treat
mm
simvastatin
sigma
hour
later
treat
either
mm
simvastatin
poli
c
mgml
sigma
treat
cell
cultur
supernat
harvest
hour
poli
c
treatment
measur
ifna
level
releas
pam
intestin
mononuclear
cell
pbmc
isol
ileum
blood
gn
pig
previous
describ
gut
pbmc
monocytederiv
macrophag
dcenrich
cell
prepar
obtain
plate
gut
mononuclear
cell
pbmc
cellsml
supplement
fb
gentamicin
ampicilin
mm
hepe
mm
lglutamin
mm
sodium
pyruv
day
harvest
adher
cell
nonadher
cell
use
dcenrich
cell
macrophageor
dcenrich
cell
cellswel
seed
onto
cell
plate
well
randomli
assign
treatment
group
treatment
simvastatin
alon
simvastatin
poli
c
poli
c
alon
cell
treat
simvastatin
manner
pam
mardindarbi
bovin
kidney
mdbk
cell
grown
mem
fb
antibioticantimycot
cell
supernat
sampl
serial
dilut
mem
ad
confluent
cell
monolay
seed
plate
previous
describ
hr
incub
media
remov
ml
vesicular
stomat
viru
plaqu
form
unitml
ad
hr
incub
ml
alamar
blue
ad
well
incub
hr
fluoresc
measur
nm
antivir
ifna
level
uml
express
reciproc
sampl
dilut
result
reduct
cytopath
effect
express
level
porcin
ldlr
nfkb
mrna
measur
cell
pam
taqman
realtim
pcr
describ
previous
slight
modif
mrna
express
normal
express
level
porcin
bactin
primer
probe
ldlr
bactin
probe
nfkb
design
geneiou
primer
design
softwar
follow
ldlr
f
cgccctccaaaacggtggct
ldlr
r
acttcggcgagcgtgggttg
ldlr
probe
bactin
f
cccacgccatcctgcgtctg
bactin
r
gtagccccgctccgtcagga
probe
nfkb
probe
probe
valu
express
mean
standard
error
mean
sem
cholesterol
level
data
among
treatment
group
analyz
kruskalw
test
nonparametr
use
statist
analysi
system
gene
express
ifna
level
data
number
cell
analyz
oneway
analysi
varianc
anova
viru
titer
undetect
log
geml
shed
period
assign
valu
log
geml
statist
analysi
mean
onset
durat
viru
shed
viral
titer
simvastatin
hunov
hunov
alon
group
h
pig
nhifnatr
untreat
pig
compar
unpair
twotail
mannwhitney
test
specif
durat
viru
shed
viral
titer
nhifnatr
untreat
pig
analyz
base
nhifna
treatment
period
ie
treatment
pid
posttreat
pid
overal
pid
fisher
exact
test
use
compar
pcrposit
rate
fecal
sampl
test
pid
pid
nhifnatr
untreat
pig
valu
consid
statist
signific
